TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2	pirtobrutinib Sensitive: A2 - Guideline pirtobrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	obinutuzumab Sensitive: A2 - Guideline obinutuzumab Sensitive : A2	obinutuzumab Sensitive: A2 - Guideline obinutuzumab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2	rituximab + alemtuzumab Sensitive: A2 - Guideline rituximab + alemtuzumab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	venetoclax + obinutuzumab Sensitive: A2 - Guideline venetoclax + obinutuzumab Sensitive : A2	venetoclax + obinutuzumab Sensitive: A2 - Guideline venetoclax + obinutuzumab Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2

TP53 mutation

Associations